Last reviewed · How we verify
URC102
At a glance
| Generic name | URC102 |
|---|---|
| Sponsor | JW Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers (PHASE1)
- A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal Impairment (PHASE1)
- Study of of URC102 to Assess the Efficacy and Safety in Gout Patients (PHASE2)
- Phase 1 Study(Additional) of URC102 in Healthy Subjects (PHASE1)
- Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients (PHASE2)
- Phase 1 Study of URC102 in Healthy Subjects (PHASE1)
- Study of URC102 to Assess the Safety and Efficacy in Gout Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- URC102 CI brief — competitive landscape report
- URC102 updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI